Gangguan Fungsi Kognitif Berkontribusi Terhadap Penurunan Kualitas Hidup Penyintas Kanker Payudara Pasca-kemoterapi

##plugins.themes.academic_pro.article.sidebar##

Published Mar 16, 2023
Download
pdf
Statistic

Downloads

Download data is not yet available.
Vol. 8 No. 2 (2020): Jurnal Dunia Keperawatan

##plugins.themes.academic_pro.article.main##

Hilman Syarif
Agung Waluyo
Yati Afiyanti
Muchtaruddin Mansyur

Abstract

Decreased cognitive function sometimes dramatically affects the function, quality of life and integration of
cancer survivors in the community. The objective of this study was to identify the relationship of cognitive
function to the quality of life of post-chemotherapy breast cancer survivors. This comparative descriptive
study uses a cross-sectional design at Dharmais Cancer Hospital, Jakarta. A total of 110 samples were
determined by purposive sampling method. The questionnaire used to identify cognitive function is the
Indonesian version of the Montreal Cognitive Assessment (MoCA), known as the MoCA-Ina. The
questionnaire used to measure quality of life is EORTC QLQ C30. A total of 69 (62.7%) respondents
experienced a decline in cognitive function. Based on cognitive function scores, the average visuospatial /
executive is 4.30 (0.80), naming 2.76 (0.45), attention 4.25 (1.16), language 2.39 (0.80), abstraction 1.63
(0.52), delayed recall 2.17 (1.01), and orientation 5.88 (036). The mean global health status score was lower
in the group with decreased cognitive function compared to the normal group, which was 56.76 (13.04) and
79.47 (10.05), p <0.001. Decreased cognitive function contributes to quality of life. Assessment of cognitive
function is recommended as a routine assessment by nurses and interventions to improve the quality of life
of survivors.

##plugins.themes.academic_pro.article.details##

How to Cite
1.
Syarif H, Waluyo A, Afiyanti Y, Mansyur M. Gangguan Fungsi Kognitif Berkontribusi Terhadap Penurunan Kualitas Hidup Penyintas Kanker Payudara Pasca-kemoterapi. jdk [Internet]. 2023 Mar. 16 [cited 2024 May 14];8(2):222-30. Available from: https://jdk.ulm.ac.id/index.php/jdk/article/view/359

References

  1. Andryszak P, Wiłkość M, Żurawski B,
  2. Izdebski P. Verbal memory in breast
  3. cancer patients treated with
  4. chemotherapy with doxorubicin and
  5. cyclophosphamide. Eur J Cancer Care
  6. (Engl). 2018;27(1):1–11.
  7. Biglia N, Bounous VE, Malabaila A,
  8. Palmisano D, Torta DME, D’Alonzo M,
  9. et al. Objective and self-reported
  10. cognitive dysfunction in breast cancer
  11. women treated with chemotherapy: A
  12. prospective study. Eur J Cancer Care
  13. (Engl). 2012;21(4):485–92.
  14. Cheung YT, Shwe M, Tan YP, Fan G,
  15. Ng R, Chan A. Cognitive changes in
  16. multiethnic Asian breast cancer
  17. patients: a focus group study. Ann
  18. Oncol. 2012 Oct;23(10):2547–52.
  19. Janelsins MC, Kohli S, Mohile SG,
  20. Usuki K, Ahles TA, Morrow GR. An
  21. Update on Cancer- and ChemotherapyRelated Cognitive Dysfunction: Current
  22. Status. Semin Oncol. 2011
  23. Jun;38(3):431–8.
  24. Jansen CE, Cooper BA, Dodd MJ,
  25. Miaskowski CA. A prospective
  26. longitudinal study of chemotherapyinduced cognitive changes in breast
  27. cancer patients. Support Care Cancer.
  28. ;19(10):1647–56.
  29. Syarif H, Waluyo A, Afiyanti Y,
  30. Mansyur M. Verbal learning and
  31. memory function and the influencing
  32. factors on breast cancer survivors: a
  33. cross-sectional study. Asian Pacific
  34. Island Nursing Journal. 4(2).
  35. Syarif H, Waluyo A, Afiyanti Y,
  36. Mansyur M. Executive function in
  37. breast cancer survivors and the
  38. influencing factors ଝ. Enfermería
  39. Clínica [Internet]. 2019;29(Insc
  40. :280–5. Available from:
  41. https://doi.org/10.1016/j.enfcli.2019.04
  42. .034
  43. Lai J-S, Butt Z, Wagner L, Sweet JJ,
  44. Beaumont JL, Vardy J, et al. Evaluating
  45. the Dimensionality of Perceived
  46. Cognitive Function. J Pain Symptom
  47. Manage. 2009 Jun;37(6):982–95.
  48. Argyriou AA, Assimakopoulos K,
  49. Iconomou G, Giannakopoulou F,
  50. Kalofonos HP. Either Called
  51. “Chemobrain” or “Chemofog,” the
  52. Long-Term Chemotherapy-Induced
  53. Cognitive Decline in Cancer Survivors
  54. Is Real. J Pain Symptom Manage. 2011
  55. Jan;41(1):126–39.
  56. Janelsins MC, Kesler SR, Ahles TA,
  57. Morrow GR. Prevalence, mechanisms,
  58. and management of cancer-related
  59. cognitive impairment. Int Rev
  60. Psychiatry. 2014 Feb;26(1):102–13.
  61. Dunia Keperawatan, Volume 8, Nomor 2, 2020 : 222-230
  62. Vardy J, Wefel JS, Ahles T, Tannock IF,
  63. Schagen SB. Cancer and cancer-therapy
  64. related cognitive dysfunction: an
  65. international perspective from the
  66. Venice cognitive workshop. Ann Oncol.
  67. Oct;19(4):623–9.
  68. Boykoff N, Moieni M, Subramanian
  69. SK. Confronting chemobrain: an indepth look at survivors’ reports of
  70. impact on work, social networks, and
  71. health care response. J Cancer Surviv.
  72. Dec;3(4):223–32.
  73. Panentu D, Irfan M. Uji validitas dan
  74. reliabilitas butir pemeriksaan dengan
  75. montreal cognitive assesment versi
  76. indonesia ( moca- ina ) pada insan pasca
  77. stroke fase recovery.
  78. ;13(April):55–67.
  79. Husein N, Lumempouw SF, Ramli Y,
  80. Herqutanto. Montreal Cognitive
  81. Assessment versi Indonesia MoCA-Ina
  82. untuk Skrining Gangguan Fungsi
  83. Kognitif. Neurona. 2010.
  84. Hoops S, Stern MB. Validity of the
  85. MoCA and MMSE in the detection of
  86. MCI and dementia in Parkinson disease.
  87. ;
  88. Eortc C, Greimel ER, Vlasic KK,
  89. Waldenstrom A, Singer S, Nordin A, et
  90. al. The European Organization for
  91. Research and Questionnaire Cervical
  92. Cancer Module.
  93. ;(September):1812–22.
  94. Kesler SR, Kent JS, O’Hara R.
  95. Prefrontal cortex and executive function
  96. impairments in primary breast cancer.
  97. Arch Neurol. 201 1;68(11):1447–53.
  98. Hedayati E, Alinaghizadeh H, Schedin
  99. A, Nyman H, Albertsson M. Effects of
  100. adjuvant treatment on cognitive
  101. function in women with early breast
  102. cancer. Eur J Oncol Nurs [Internet].
  103. ;16(3):315–22. Available from:
  104. http://dx.doi.org/10.1016/j.ejon.2011.0
  105. 006
  106. Peelle JE, Cusack R, Henson RNA.
  107. Adjusting for global effects in voxelbased morphometry: Gray matter
  108. decline in normal aging. Neuroimage
  109. [Internet]. 2012;60(2):1503–16.
  110. Available from:
  111. http://dx.doi.org/10.1016/j.neuroimage.
  112. 12.086
  113. Biro Pusat Statistik. Indikator
  114. pendidikan 1994-2017. 2017. Diakses
  115. dari
  116. https://www.bps.go.id/statictable/2010/
  117. /19/1525/indikator-pendidikan-1994-
  118. html
  119. Kementerian Pemberdayaan Perempuan
  120. dan Perlindungan Anak. Profil
  121. Perempuan Indonesia 2018. Jakarta:
  122. Kementerian pemberdayaan perempuan
  123. dan perlindungan anak. 2018
  124. Hess LM, Insel KC. ChemotherapyRelated Change in Cognitive Function:
  125. A Conceptual Model. Oncol Nurs
  126. Forum. 2007;34(5):981 –94.
  127. Ahles TA, Root JC, Ryan EL. Cancerand Cancer Treatment-Associated
  128. Cognitive Change: An Update on the
  129. State of the Science. J Clin Oncol. 2012
  130. Oct;30(30):3675–86.
  131. Oh PJ. Predictors ofcognitive decline in
  132. people with cancer undergoing
  133. chemotherapy. Eur J Oncol Nurs
  134. [Internet]. 2017;27:53–9. Available
  135. from:
  136. http://dx.doi.org/10.1016/j.ejon.2016.1
  137. 007
  138. Joly F, Giffard B, Rigal O, De Ruiter
  139. MB, Small BJ, Dubois M, et al. Impact
  140. of Cancer and Its Treatments on
  141. Cognitive Function: Advances in
  142. Research from the Paris International
  143. Cognition and Cancer Task Force
  144. Symposium and Update since 2012. J
  145. Pain Symptom Manage.
  146. ;50(6):830–41.
  147. Lenzi R, Theriault RL, Davis RN, Ph D,
  148. Meyers CA, Ph D. The Cognitive
  149. Sequelae of Standard-Dose Adjuvant
  150. Results of a Prospective , Randomized ,
  151. Longitudinal Trial. 2004;(April):2292–
  152. Gaman AM, Uzoni A, Popa-Wagner A,
  153. Andrei A, Petcu E-B. The Role of
  154. Oxidative Stress in Etiopathogenesis of
  155. Chemotherapy Induced Cognitive
  156. Impairment (CICI)-“Chemobrain.”
  157. Aging Dis. 2018;7(3):307.
  158. M. B, A.R. B, B. D. Impact of
  159. chemotherapy on memory, attention and
  160. executive functions depending on the
  161. stages of treatment and the level of
  162. depression in female patients with
  163. cancer. Acta Neuropsychol [Internet].
  164. ;12(4):417–27. Available from:
  165. Syarif H, Waluyo A, Afiyanti Y, Mansyur M. Gangguan Fungsi Kognitif
  166. http://www.embase.com/search/results?
  167. subaction=viewrecord&from=export&i
  168. d=L602144385%0Ahttp://dx.doi.org/1
  169. Cheng ASK, Lau LOC, Ma YNH, Ngai
  170. RH, Fong SSL. ScienceDirect Impact of
  171. Cognitive and Psychological Symptoms
  172. 5604/17307503.1138845%0Ahttp://r on Work Productivity and Quality of
  173. ug.on.worldcat.org/atoztitles/link/?sid= Life among Breast Cancer Survivors in
  174. EMBASE&issn=17307503&id=doi:10. Hong Kong. Hong Kong J Occup Ther
  175. %2F17307503.1138845&atitle=I [Internet]. 2016;28:15–23. Available
  176. mpact+of+chem from:
  177. Mihuta ME, Green HJ, Man DWK, http://dx.doi.org/10.1016/j.hkjot.2016.1
  178. Shum DHK. Correspondence between 1.002
  179. Subjective and Objective Cognitive 31. Hsu T, Ennis M, Hood N, Graham M,
  180. Functioning Following Chemotherapy Goodwin PJ. J ournal of clinical
  181. for Breast Cancer. Brain Impair. oncology. Quality of Life in Long-Term
  182. ;17(3):222–32. Breast Cancer Survivors. 2020;31(28).